Pratt C B, Goren M P, Meyer W H, Singh B, Dodge R K
Departments of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38101-0318.
J Clin Oncol. 1990 Aug;8(8):1399-401. doi: 10.1200/JCO.1990.8.8.1399.
Neurotoxicity developed in 22 of 97 children and adolescents with malignant solid tumors treated within a phase II ifosfamide protocol. The occurrence of neurotoxicity was related to previous cumulative dosages of cisplatin. One third of the patients who had received more than 600 mg/m2 of cisplatin developed this complication. The relative risk increased 3.2-fold with previous cisplatin dosages above 301 to 600 mg/m2, and 4.1-fold with dosages of 601 to 1,340 mg/m2. The increased risk of neurotoxicity in patients who had received more than 600 mg/m2 of cisplatin may be related to either a decreased clearance of ifosfamide itself or of the drug's active metabolites.
在一项II期异环磷酰胺方案治疗的97例儿童和青少年恶性实体瘤患者中，有22例出现了神经毒性。神经毒性的发生与顺铂先前的累积剂量有关。接受超过600mg/m²顺铂的患者中有三分之一出现了这种并发症。先前顺铂剂量高于301至600mg/m²时，相对风险增加3.2倍；剂量为601至1340mg/m²时，相对风险增加4.1倍。接受超过600mg/m²顺铂的患者神经毒性风险增加，可能与异环磷酰胺本身或其活性代谢产物的清除率降低有关。
